Everest Medicines’ Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
Thursday, 21 December 2023
Shanghai, China – Dec. 21, 2023 — Everest Medicines (HKEX 1952.HK, "Everest", or the "Company”)’s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon® delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Nefecon® was first approved in December 2021 under the FDA accelerated approval pathway and is now the first fully FDA-approved treatment for IgAN based on a measure of kidney function.
• The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels.
• Nefecon® is now approved by the FDA with a confirmed and statistically significant benefit over placebo (p
|
||||
|
|
||||
You Might LikeRelated news from verified sources
|
||||
